ClinicalTrials.gg
Active, not recruitingNCT04857372Updated Jun 22, 2026

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

A Phase 1 interventional study of IAG933 in Mesothelioma, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 16 sites in 11 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
137
Allocation
Non-randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Mesothelioma with a site in United States — 35 open to participants now, 51 under way, 1 of them phase 3. Mesothelioma · United States.

Enrollment
38th of 165
137 · median 44
Started
2021
with 14 others
Phase 1
75 of 189
9 open now
Primary completion
2027-01
later than 10 of 50 live
Registered
143rd of 189
by date
Lead sponsor
5 of 189
Novartis Pharmaceuticals

Among the 189 studies in Mesothelioma with a site in United States, this one is the 38th largest by enrollment of the 165 interventional ones that give a count, is one of 15 that started in 2021, is one of 75 in phase 1, reaches primary completion later than 10 of the 50 other live ones, and was the 143rd registered.

Mesothelioma

305 studies on the registry are indexed under Mesothelioma; 59 are open to participants now.

Browse Mesothelioma studies →

Open to participants now

35 of the 189 studies in Mesothelioma with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Mesothelioma studies recruiting now, 32 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Mesothelioma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.

Read the detailed description

This is a phase I, open-label, multi-center study of IAG933 as a single agent consisting of a dose escalation part, followed by a dose expansion part. The escalation part will characterize the safety and tolerability. After the determination of the recommended dose/maximum tolerated dose, dose expansion will assess the preliminary anti-tumor activity in defined patient populations and further assess the safety and tolerability at RD/MTD.

03

Conditions studied

  • Mesothelioma

Browse trials for

Keywords

  • Mesothelioma
  • IAG933
  • NF2 mutated tumors
  • LATS1/LATS2 mutated tumors
  • YAP/TAZ
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to participation in the study.
  2. Male or female patients must be ≥ 18 years of age.
  3. Dose escalation part: patients with or cytologically confirmed diagnosis of advanced (unresectable or ) mesothelioma or other solid tumors. Patients with solid tumors other than mesothelioma must have local available data for loss-of-function NF2/LATS1/LATS2 genetic alterations (truncating mutation or gene deletion; LATS1/LATS2 mutations will only be included in the dose escalation part), or functional YAP/TAZ fusions. Patients with malignant EHE can be enrolled with only histological confirmation of the disease. Patients must have failed available standard therapies, be intolerant of or ineligible for standard therapy, or for whom no standard therapy exists.
  4. Dose expansion part: the following patients will be enrolled into 3 different treatment groups:

    Group 1: Advanced (unresectable or metastatic) MPM patients who have failed available standard therapies for advanced/metastatic disease, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.

    Group 2: Advanced (unresectable or metastatic) solid tumor patients with available local data for NF2 truncating mutation or deletions. Patient must have failed available standard therapies, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.

    Group 3: Advanced (unresectable or metastatic) solid tumor patients with available local data for functional YAP/TAZ fusions. EHE patients can be included with only histological confirmation of the disease. Patient must have failed available standard therapies, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.

    Group 4: Advanced (unresectable or metastatic) non-pleural mesothelioma patients who have failed available standard therapies for advanced/metastatic disease, are intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.

  5. Presence of at least one according to v1.1 for mesothelioma patients, v1.1 for patients with other solid tumors, or RANO for patients with primary brain tumors.
  6. Patient must have a site of disease amenable to and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening/baseline, and again during therapy on this study. An archival tumor sample may be used at screening. During the dose expansion part of the study, a decision may be made to stop the collection of on-treatment biopsies.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:

    1. ≤ 4 weeks for thoracic radiotherapy to lung fields or limited field radiation for palliation within ≤ 2 weeks prior to the first dose of study treatment. An exception to this exists for patients who have received palliative radiotherapy to bone, who must have recovered from radiotherapy-related toxicities but for whom a 2-week is not required.
    2. ≤ 4 weeks or ≤ 5 half-lives (whichever is shorter) for biological therapy (including monoclonal antibodies) or continuous or intermittent small molecule therapeutics or any other agent.
    3. ≤3 weeks for treatment with cytotoxic agents or ≤ 6 weeks for cytotoxic agents with risk of major delayed toxicities, such as nitrosoureas and mitomycin C.
    4. ≤ 4 weeks for immuno-oncologic therapy, such as CTLA4, , or PD-L1 antagonists
    5. Prior treatment with TEAD inhibitor at any time
  2. For mesothelioma patients: use of non-invasive antineoplastic therapy (e.g., tumor treating fields, brand name Optune LuaTM) within 2 weeks of the tumor assessment at screening.
  3. Malignant disease, other than that being treated in this study.
  4. Insufficient renal function at Screening.
  5. cardiac disease or risk factors at screening
  6. Insufficient bone marrow function at screening.
  7. Insufficient hepatic function at screening.
  8. Patients who have the following laboratory values > (CTCAE) grade 1:

    1. Potassium
    2. Magnesium
    3. Total calcium (corrected for low serum albumin)
  9. Known active COVID-19 infection.
  10. Pregnant or nursing (lactating) women,
  11. Japan only: patients with a history of drug- and/or non-drug-induced interstitial lung disease (ILD) ≥ Grade 2.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Group 1

    Malignant pleural mesothelioma

    Drug: IAG933

  • Experimental
    Group 2

    NF2 truncating mutations or deletions

    Drug: IAG933

  • Experimental
    Group 3

    Solid tumors with functional YAP/TAZ fusions

    Drug: IAG933

  • Experimental
    Group 4

    Non-pleural mesothelioma

    Drug: IAG933

Interventions

  • DrugIAG933

    Capsule

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events and serious adverse events

    Safety and tolerability of IAG933

    Time frame: 3 years

  2. Incidence of dose limiting toxicities during the first treatment cycle (dose escalation only)

    Safety, tolerability and the maximum tolerated dose or recommended dose of IAG933

    Time frame: 1 year

  3. Number of patients with dose interruptions and dose changes

    Tolerability of IAG933

    Time frame: 3 years

Secondary outcomes

  1. Overall response rate (ORR)

    Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma patients), and RANO (for patients with primary brain/CNS tumors)

    Time frame: 3 years

  2. Disease control rate (DCR)

    Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma), and RANO (for patients with primary brain/CNS tumors)

    Time frame: 3 years

  3. Progression free survival (PFS)

    Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma patients), and RANO (for patients with primary brain/CNS tumors)

    Time frame: 3 years

  4. Duration of response (DOR)

    Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma patients), and RANO (for patients with primary brain/CNS tumors)

    Time frame: 3 years

  5. Overall survival (OS) (dose expansion only)

    Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma patients), and RANO (for patients with primary brain/CNS tumors)

    Time frame: 3 years

  6. Minimum serum concentration (Cmin) (dose escalation only)

    Characterize PK of IAG933

    Time frame: 1 year

  7. Maximum serum concentration (Cmax)

    Characterize PK of IAG933

    Time frame: 3 years

  8. Time to reach Cmax (Tmax)

    Characterize PK of IAG933

    Time frame: 3 years

  9. Area under the curve (AUC)

    Characterize PK of IAG933

    Time frame: 3 years

  10. Half life (T1/2) (dose escalation only)

    Characterize PK of IAG933

    Time frame: 1 year

  11. Accumulation ratio (Racc) (dose escalation only)

    Characterize PK of IAG933

    Time frame: 1 year

07

Study locations

16 sites
  • University of California LA
    Los Angeles, California 90095, United States
  • Uni of Chi Medi Ctr Hema and Onco
    Chicago, Illinois 60637, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030 4009, United States
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Montreal, Quebec H2W 1T8, Canada
  • Novartis Investigative Site
    Villejuif, 94800, France
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Milan, MI 20133, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Chuo Ku, Tokyo 1040045, Japan
  • Novartis Investigative Site
    Rotterdam, South Holland 3015 GD, Netherlands
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Manchester, M20 2BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Jan 2027, 62 months after the start.

Of 42 phase 1 interventional studies under Mesothelioma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 62 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2021
First posted
Apr 23, 2021
StartActual
Oct 21, 2021
Primary completionEst.
Jan 7, 2027
CompletionEst.
Jan 8, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04857372
Responsible party
Sponsor
First posted
Apr 23, 2021
Start date
Oct 21, 2021
Primary completion
Jan 7, 2027 (estimated)
Completion
Jan 8, 2027 (estimated)
Last update
Jun 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion